Benzinga | Nov 10, 2021 06:59AM EST

Codex DNA Clocks Q3 Sales Growth Of 75%; Acquires Eton Bioscience For $13M

* Codex DNA Inc's (NASDAQ:DNAY) Q3 revenues increased 75% Y/Y to $2.8 million. The total fell short of the consensus Wall Street estimate of $2.93 million.

* Q3 was the first full quarter for Codex as a public company. The firm completed a $122.7 million initial public offering in June.

* The EPS loss lowered to $(0.34) from $(0.89), but missing the consensus of $(0.28).

* Codex DNA had $109.8 million in cash and equivalents.

* Codex has acquired Eton Bioscience, a startup that offers synthetic biology products and services, including DNA sequencing and oligo synthesis, for $13 million in cash.

* With the acquisition, Codex expects to accelerate the growth of its BioXp synthetic biology benchtop system.

* Eton Bioscience, founded in 2003 and privately held, generated $5.1 million in revenues for the nine months ended September 30.

* Price Action: DNAY shares are up 0.11% at $9.29 during the premarket session on the last check Wednesday.